Azora Therapeutics, Inc. has reported a change in ownership through a recent SEC filing. The company submitted a Form 3 on November 10, 2026, which details ownership changes involving its director, Thomas M. Soloway. This filing is significant as it underscores the company's commitment to transparency and adherence to regulatory requirements.

Background

Azora Therapeutics, Inc. is a Delaware-based company operating in the pharmaceutical preparations sector, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol AZR. Recent filings include a Form 8-K on November 12, 2026, and a Form 10-Q on the same date, indicating active financial reporting and compliance efforts.

What the Filing Says

The Form 3 filing indicates that Thomas M. Soloway has a reporting obligation due to his position as a director. The filing states, "The date as of change: 2026-11-10," which marks the effective date of this ownership change. Additionally, the filing includes a Power of Attorney document, allowing designated individuals to act on behalf of the reporting owner.

Impact

This ownership change may affect the governance structure of Azora Therapeutics, particularly in terms of decision-making processes within the company. As a smaller reporting company, Azora's activities could also influence other companies in the pharmaceutical preparations sector, as they may observe and respond to similar ownership changes.

What's Next

The filing does not say what happens next. However, it is likely that further disclosures will follow as the company continues to comply with SEC regulations and manage its ownership structure.